The global Alzheimer's therapeutics market size was valued at USD 4.04 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 16.2% from 2022 to 2030. The rising prevalence of Alzheimer’s disease and approval of disease-modifying therapies are expected to fuel market growth. According to the NCBI, in 2021, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer's disease, which is estimated to increase to around 13.8 million by 2060. Women are more prone to be diagnosed with Alzheimer’s disease than men due to the longer life expectancy of women. Moreover, Alzheimer's disease is becoming the most common cause of death in neurodegenerative diseases and a common cause of physical disability that require immediate treatment.
The impact of the COVID-19 pandemic on the market was negative due to strict measures undertaken by the government such as lockdown to control infection spread. During the pandemic, the prescription rate for drugs used to treat Alzheimer’s was lowered due to a decline in patient visits to clinics and hospitals for treatment and fear of COVID infection, thereby restraining market growth.
The introduction of new highly sensitive cloud-based cognitive assessment systems will help pharmaceutical companies identify drug effects in patients. This will help pharmaceutical companies evaluate the cognitive efficacy and safety of pipeline AD therapeutics. Cambridge Cognition’s Cantab Connect product has been specifically developed for measuring the effectiveness of drugs being developed for mild, moderate, and prodromal AD. The usage of this technology will increase the likelihood of product approvals, thereby driving the AD treatment market.
The uncertainty, failure, and discontinuation of the clinical trials of Alzheimer's drugs lead to the availability of limited treatment alternatives. This increases the costs related to research and development. Hence, it is expected to restrain the market growth. For instance, Amgen Inc. and Novartis AG discontinued their Phase 2 clinical trial for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer's disease, in July 2019, due to the lack of desired results.
The cholinesterase inhibitors segment held the largest revenue share of over 50.0% in 2021 as it is the standard of care for Alzheimer’s treatment. In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc., for the treatment of patients with severe dementia of Alzheimer’s disease (AD). It is a transdermal patch administered once a week and delivers a stable dose of donepezil and was the fourth cholinesterase drug approved and launched in the U.S. Based on product, the market is divided into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs.
The pipeline drugs segment is expected to witness the fastest growth over the forecast period owing to the impending launch of multiple disease-modifying therapies. Companies such as F. Hoffmann La Roche Ltd.; Biogen/Eisai Inc.; and Eli Lilly and Company have drug candidates under development that will modify the treatment landscape of AD. According to Alzheimer’s Association, there were 143 drug candidates in 172 clinical trials for AD. Of these, 31 drug candidates in phase 3 clinical trial, 82 drug candidates in phase 2, and 30 drug candidates in phase 1. Successful completion of trials and subsequent approval of these products are anticipated to boost the market growth.
The hospital pharmacy segment dominated the market in 2021 with a revenue share of over 55.0% owing to the increasing hospitalization due to a rise in the geriatric population and Alzheimer’s patients. According to Alzheimer’s Association report 2022, there are 518 hospitalizations per 1,000 Medicare beneficiaries in the geriatric population having Alzheimer’s or other dementias as compared to only 234 hospitalizations per 1,000 Medicare beneficiaries without these conditions. However, the total number of hospitalizations of AD patients is expected to remain low compared to the prevalence of Alzheimer’s disease.
The e-commerce segment is expected to expand at a CAGR of 15.33% over the forecast period. An increase in the usage of the internet and smartphone, ease of ordering medications through an e-commerce platform, and increasing e-commerce services globally are expected to fuel the segment growth in the coming years.
North America dominated the market with a share of over 40.0% in 2021 and is anticipated to grow at a significant rate over the forecast period. The growing research for the treatment of Alzheimer’s is propelling the market growth. In June 2021, Eisai Co., Ltd. and Biogen's product lecanemab (BAN2401), an anti-amyloid beta protofibril antibody for treating Alzheimer's disease, was granted the Breakthrough Therapy designation by the U.S. FDA. Moreover, the increasing government initiatives and funding are expected to boost the growth of the market.
The Asia Pacific region is expected to emerge as the fastest-growing region over the forecast period owing to increasing awareness among people and the increasing research activities to develop novel drugs to treat AD. In 2022, there are around 487,500 Australians living with dementia and this number is expected to increase to 1.1 million by 2058. Dementia is the second leading cause of death in Australia.
New product launches and R&D investments are some of the key strategies adopted by the key players to acquire a greater market share. For instance, in June 2021, Eisai/Biogen received approval for its anti-amyloid antibody, Aduhelm, for the treatment of AD. The company also has another product, lecanemab, in the pipeline. The U.S. FDA has accepted the BLA for lecanemab and is expected to provide a decision on its approval by January 2023. Some prominent players in the global Alzheimer’s therapeutics market include:
Eisai Co., Ltd.
Novartis AG
AbbVie Inc. (Allergan Plc.)
Adamas Pharmaceuticals, Inc.
H. Lundbeck A/S
Biogen
AC Immune
F. Hoffmann La Roche Ltd.
Daiichi Sankyo Company, Limited
Johnson & Johnson Services, Inc.
TauRx Pharmaceuticals Ltd.
Alzheimer’s Therapeutics Market Report Scope
Report Attribute |
Details |
Market size value in 2022 |
USD 4.20 billion |
Revenue forecast in 2030 |
USD 15.6 billion |
Growth rate |
CAGR of 16.2% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, end-user, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; |
Key companies profiled |
Eisai Co., Ltd.; Novartis AG; AbbVie Inc. (Allergan Plc.); Adamas Pharmaceuticals, Inc.; H. Lundbeck A/S; Biogen; AC Immune; F. Hoffmann La Roche Ltd.; Daiichi Sankyo Company, Limited; Johnson & Johnson Services, Inc.; TauRx Pharmaceuticals Ltd. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global Alzheimer’s therapeutics market report based on product, end-user, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Cholinesterase Inhibitors
NMDA Receptor Antagonist
Combination Drug
Pipeline Drugs
End-user Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacy
Retail Pharmacy
E-commerce
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global Alzheimer's therapeutics market size was estimated at USD 4.04 billion in 2021 and is expected to reach USD 4.20 billion in 2022.
b. The global Alzheimer's therapeutics market is expected to grow at a compound annual growth rate of 16.2% from 2022 to 2030 to reach USD 15.6 billion by 2030.
b. North America dominated the Alzheimer's therapeutics market with a share of 40.76% in 2021. This is attributable to the favorable regulatory policies, high target patient population and better treatment rates for AD.
b. Some key players operating in the Alzheimer's therapeutics market include Novartis AG, Allergan (AbbVie), Johnson & Johnson Services, Inc., Biogen, Eisai Co., Ltd., Johnson & Johnson Services, Novartis AG, AC Immune, H. Lundbeck A/S, and DAIICHI SANKYO COMPANY, LIMITED
b. Key factors that are driving the Alzheimer's therapeutics market growth include the increasing prevalence of the disease, the rising geriatric population, and the approval & launch of disease-modifying therapies such as anti-amyloid monoclonal antibodies for the treatment of AD.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for COVID-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for COVID-19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.